These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Immuneering (IMRX) announced a clinical supply agreement with Regeneron Pharmaceuticals (REGN) for its anti-PD-1 therapy, Libtayo. The supply ...

CAMBRIDGE, Mass. - Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company with a market capitalization of $59.31 million, has entered into a clinical supply agreement with Regeneron ...

Researchers evaluated a neoantigen-targeting personalized cancer vaccine in patients with high-risk, fully resected clear ...

An international study published in the New England Journal of Medicine provides hope for chronic lymphocytic leukemia (CLL) ...

Researchers uncover key mechanisms in gene regulation that may lead to better design of RNA-based medicines.

Researchers report that all nine patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma (a form of kidney cancer), generated a successful anti-cancer immune ...

A research team affiliated with UNIST has unveiled an innovative technology to eliminate drug-resistant cancer cells using ...

The lab of The Wistar Institute's Jessie Villanueva, Ph.D., has identified a new strategy for attacking treatment-resistant melanoma: inhibiting the gene S6K2. .

Strong private equity investment and strategic M&A in 2024, and a shift toward clinical-stage companies and asset-driven ...